Skip to content
Skip to navigation menu
01 April 2011
Inhibitex, the US biopharmaceutical company working on potential anti-viral drugs with Prof Chris McGuigan’s laboratory in the Welsh School of Pharmacy, has just announced the successful conclusion of the initial phase 1 trials of INX-189 in hepatitis C patients.
This drug, first synthesised less than three years ago in the laboratory in the Welsh School of Pharmacy, is active against Hepatitis C. This disease affects some 170 million individuals worldwide (3 per cent of the human population) and current treatment is unsatisfactory. In the current trial, around 50 HCV patients received either a daily oral dose of INX-189, ranging from 3 mg to 100 mg, in some cases in combination with the current drug Ribavarin, for 7 days. The Company plans to present detailed results from this trial during a future scientific meeting. Preliminary data from the trial includes:
Professor McGuigan, who is also a member of the Board of Directors of Inhibitex, warmly welcomed this news, saying: "The outcome of these multiple dose studies in patients on INX-189 are exciting and continue to show the effectiveness of the drug in patients with hepatitis C. We now need to continue with a full phase II clinical study. INX-189 has today taken a major step closer to becoming a much needed new drug for hepatitis C infection."
For recent scientific papers describing the development of INX-189 see Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus Christopher McGuigan, Karolina Madela, Mohamed Aljarah, et al. Bioorganic & Medicinal Chemistry Letters 20 (2010) 4850–4854 and Phosphoramidate ProTides of 2’-C-Methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties. C. McGuigan, A. Gilles, K. Madela, M. Aljarah, et al. J. Med. Chem., 2010, 4949-4957.
A current Powerpoint presentation from Prof McGuigan describing Pro Tides is available here. Inhibitex, Inc.
Milestone for anti-shingles drug
Developing new anti-cancer medicines
New vaccine hope for leading viral cause of birth defects
'War Horse' author tops Cardiff Children’s Literature Festival
Cardiff leads largest ever Alzheimer’s study
The origins of breast cancer
This is an externally hosted beta service offered by Google.